Navigation Links
ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
Date:6/3/2008

SAN DIEGO, June 3 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced today that it presented objective response rate and available safety data from the Company's Phase 2 clinical study of ANX-510, or CoFactor(R), for the treatment of advanced breast cancer at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting, which takes place May 30 - June 3, 2008 in Chicago, IL. CoFactor plus 5-FU (5-Fluorouracil) was determined to be a safe, well-tolerated and active treatment regimen in advanced breast cancer patients who are Herceptin receptor (Her2/neu) negative and who have failed prior taxane and anthracycline therapies. Data available from 31 patients indicated a 23% objective response rate with CoFactor plus 5-FU based on investigators' assessments. Objective response rate was based on the number of complete responses and partial responses observed in this study.

The poster presentation, entitled "5,10 methylenetetrahydrofolic acid with 5-fluorouracil as treatment for advanced breast cancer in patients who failed prior treatment with anthracyclines and taxanes: A phase 2 study," was presented by Dr. Joachim P.H. Schupp, Vice President of Medical Affairs on June 2, 2008.

Historically, capecitabine (Xeloda(R)), a widely-used treatment for advanced breast cancer, has demonstrated response rates between 14% and 26% when studied as monotherapy in patients with advanced breast cancer who failed prior treatment with anthracyclines and taxanes. In this well-defined study population, two recently published, Phase 3 clinical trials, where capecitabine was the approved therapy, demonstrated response rates of 14% for capecitabine alone compared with 35% for capecitabine in combination with ixabepil
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
8. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
9. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
10. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
11. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013  Net Medical Xpress Solutions, Inc., (OTC QB: ... the company has signed a letter of intent to ... Huntsville, AL . MedTel Solutions is ... and recruitment of telemedicine physicians. Consideration for the acquisition ... which is expected by June 30, 2013. ...
(Date:5/23/2013)... Md. , May 23, 2013  BioElectronics Corporation ... consumer medical devices, comments on the FDA panel meeting ... Advisory Panel Reclassification – Pulsed Shortwave Therapy Meeting was ... MD , USA.  The focus of the meeting ... the panel to focus solely on the application of ...
(Date:5/23/2013)... Israel Brain Technologies (IBT) has announced ... Israel,s 1 st International Brain Technology Conference, ... in Tel Aviv , recently ranked ... world by the Wall Street Journal and the ... will showcase the latest breakthroughs in neuroscience and brain technology ...
Breaking Medicine Technology:Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 2Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 3BioElectronics and Pulsed Shortwave Therapy Make Progress 2Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3
... Masimo (Nasdaq: MASI ) announced today that ... ended October 2, 2010, after the market closes on November 2, ... begin at 1:30 p.m. PT (4:30 p.m. ET) and will be ... P. de Raad, Executive Vice President and Chief Financial Officer. ...
... MacroGenics, Inc. and Eli Lilly and Company (NYSE: ... Monitoring Committee (DMC), composed of independent experts in the ... analysis of one-year safety and efficacy data of the ... biologic under development for the treatment of individuals with ...
Cached Medicine Technology:Masimo to Report Third Quarter 2010 Financial Results After Market Close on November 2, 2010 2Masimo to Report Third Quarter 2010 Financial Results After Market Close on November 2, 2010 3MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint 2MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint 3
(Date:5/23/2013)... , , WEDNESDAY, May 22 (HealthDay News) -- The success of ... born with a serious airway malformation sheds light on new ... A report in the May 23 New England Journal ... At first, the baby born five weeks early seemed ... eating when he was 6 weeks old. Just two weeks ...
(Date:5/23/2013)... HealthDay Reporter , , WEDNESDAY, May 22 (HealthDay News) ... for detecting lung cancer now have more information to help ... study finds that low-dose CT scans pick up significantly more ... long history of smoking are at high risk for lung ... But doctors have to consider the potential harm of radiation ...
(Date:5/23/2013)... According to a new market report "Service ... Data Management (SDM); Telecom Application Server; Service Creation Environment; ... 2018)", published by MarketsandMarkets, the SDP Market is expected ... of 9.15% from 2013 to 2018. , Browse:, ... 84 Figures , 189 Pages and ...
(Date:5/23/2013)... May 23, 2013 DRE, Inc. is ... as a solution to upgrade older model DRE ... the entire lighting system. , DRE and BFW ... DRE or BFW halogen headlights to LED with DRE’s ... C3 LED Conversion Kit provides a bright, clean and ...
(Date:5/23/2013)... Located at 22343 La Palma Ave. #125, ... its Grand Opening Family Fun Charity event on May 11, ... and physical fitness. Sponsored by many different vendors like Chick-fil-a ... filled Grand Opening featured mini boot camp sessions and raffled ... the Yorba Linda fitness center has to offer. ...
Breaking Medicine News(10 mins):Health News:Docs Use 3-D Printer to Create Lifesaving Airway Device for Infant 2Health News:Docs Use 3-D Printer to Create Lifesaving Airway Device for Infant 3Health News:CT Scans Reduce Lung Cancer Deaths, Study Confirms 2Health News:CT Scans Reduce Lung Cancer Deaths, Study Confirms 3Health News:Service Delivery Platform (SDP) Market Is Growing at a CAGR of 9.15% & to Reach $6.94 Billion by 2018 - New Report by MarketsandMarkets 2Health News:Service Delivery Platform (SDP) Market Is Growing at a CAGR of 9.15% & to Reach $6.94 Billion by 2018 - New Report by MarketsandMarkets 3Health News:New DRE, Inc. LED Conversion Kit Allows Doctors to Upgrade Older Halogen Technology Without Replacing Entire Lighting Systems 2Health News:New DRE, Inc. LED Conversion Kit Allows Doctors to Upgrade Older Halogen Technology Without Replacing Entire Lighting Systems 3Health News:Yorba Linda Personal Trainer Celebrates Fit Body Boot Camp Yorba Linda Grand Opening by Hosting a Family Fun Charity Event 2Health News:Yorba Linda Personal Trainer Celebrates Fit Body Boot Camp Yorba Linda Grand Opening by Hosting a Family Fun Charity Event 3
... Florida,s elected leaders,received a message from thousands ... Governor Charlie Crist and legislative leaders not to,eliminate ... the state,s most,vulnerable citizens., Driven by ambulance ... gurney,the petitions ask Governor Crist, Senate President Ken ...
... Corporation,(Nasdaq: HSKA ) announces the following Webcast:, What: Heska ... Stockholders on the Web, When: Tuesday, ... the Annual Meeting of Stockholders ... over the Internet -- Simply log on to the web at the ...
... a myocardial infarction is not higher for women than ... International (Dtsch Arztebl Int 2008; 105(15): 279-85), PD Dr. ... widely held view. , ( http://www.aerzteblatt-international.de/v4/archiv/pdf.asp?id=59860 ) , ... from AOK (a large general statutory health insurance company) ...
... -- Chindex International,Inc. (Nasdaq: CHDX ) a ... products in the People,s Republic of China, today,announced ... presentations at,the following investment conferences in New York ... All-China Conference being held,from May 19-20, 2008 at ...
... GHX honored 14 healthcare,provider and supplier organizations with its ... awards were,presented on Friday, April 18, 2008 during a ... Chain Summit, the largest healthcare,forum in the U.S. focused ... supply,chain., The theme of this year,s awards was ...
... men and often compresses the urethra resulting in voiding ... to measure the resistance of the urethra using sound: ... spectrum of the recorded sound depends on how much ... with voiding symptoms, such as a weak urinary stream ...
Cached Medicine News:Health News:Thousands Sign Petitions Urging Governor Crist and Legislative Leaders to Save Healthcare Coverage for 40,000 Floridians 2Health News:Thousands Sign Petitions Urging Governor Crist and Legislative Leaders to Save Healthcare Coverage for 40,000 Floridians 3Health News:Webcast Alert: Heska Corporation's Annual Meeting of Stockholders Webcast 2Health News:Chindex International, Inc. to Present at China Investment Conferences in New York City - May 20, 21, 22; Conferences Presented By Brean Murray, Carret & Co., Oppenhiemer & Co. and Citigroup 2Health News:Chindex International, Inc. to Present at China Investment Conferences in New York City - May 20, 21, 22; Conferences Presented By Brean Murray, Carret & Co., Oppenhiemer & Co. and Citigroup 3Health News:GHXcellence Awards Honor Healthcare Providers and Suppliers for Achievements in Supply Chain Performance 2Health News:GHXcellence Awards Honor Healthcare Providers and Suppliers for Achievements in Supply Chain Performance 3
CVC 123 is an assayed quality control material used for confirming the calibration and linearity of blood gas, electrolyte, and metabolite instrumentation....
... assayed quality control material used for monitoring the ... It is for specific use on Bayer analyzers ... 288, and 270) and the AVOX Systems CO-Oximeters ... used on the IRMA TRUpoint®. CC 527 is ...
... a quality control material that, once tonometered, ... blood gas, electrolyte, metabolite, and CO-Oximeter instrumentation. ... use of human blood in tonometry. QC ... for monitoring analyzer performance at varying points ...
... is an assayed quality control material ... blood gas, electrolyte, metabolite, and CO-Oximeter ... control makes it the ideal choice ... is available in three (3) levels ...
Medicine Products: